BLRX
BioLineRx Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.59
P/S
9.10
EV/EBITDA
-5.37
DCF Value
$0.24
FCF Yield
-76.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.1%
Operating Margin
-874.7%
Net Margin
-101.7%
ROE
-6.1%
ROA
-2.9%
ROIC
-30.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $195.2K | $-1.4M | $-0.32 |
| FY 2025 | $1.2M | $-1.2M | $-0.29 |
| Q3 2025 | $427.0K | $-977.0K | $-0.22 |
| Q2 2025 | $304.0K | $-3.9M | $-1.00 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
0.48
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.